Hennion & Walsh Asset Management Inc. Purchases 1,970 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Hennion & Walsh Asset Management Inc. grew its position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 84.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,297 shares of the biotechnology company's stock after acquiring an additional 1,970 shares during the quarter. Hennion & Walsh Asset Management Inc.'s holdings in United Therapeutics were worth $1,325,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of UTHR. Cerity Partners LLC grew its holdings in United Therapeutics by 30.4% during the fourth quarter. Cerity Partners LLC now owns 11,588 shares of the biotechnology company's stock worth $4,098,000 after buying an additional 2,702 shares in the last quarter. Korea Investment CORP grew its holdings in United Therapeutics by 6.2% during the fourth quarter. Korea Investment CORP now owns 39,289 shares of the biotechnology company's stock worth $13,863,000 after buying an additional 2,300 shares in the last quarter. Illumine Investment Management LLC bought a new stake in United Therapeutics during the fourth quarter worth $3,015,000. ExodusPoint Capital Management LP bought a new stake in United Therapeutics during the fourth quarter worth $1,899,000. Finally, Raymond James Financial Inc. bought a new stake in United Therapeutics during the fourth quarter worth $18,257,000. Institutional investors own 94.08% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. HC Wainwright reiterated a "buy" rating and set a $425.00 price target on shares of United Therapeutics in a report on Monday, May 5th. Cantor Fitzgerald assumed coverage on United Therapeutics in a report on Monday, June 2nd. They set an "overweight" rating and a $405.00 price target for the company. Wall Street Zen downgraded United Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Friday, May 2nd. Morgan Stanley boosted their price objective on United Therapeutics from $346.00 to $348.00 and gave the stock an "equal weight" rating in a research report on Thursday, May 1st. Finally, JPMorgan Chase & Co. cut their price objective on United Therapeutics from $355.00 to $350.00 and set an "overweight" rating on the stock in a research report on Thursday, May 1st. Four equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. Based on data from MarketBeat, United Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $393.00.

Insider Activity

In related news, Director Tommy G. Thompson sold 2,500 shares of the stock in a transaction dated Monday, March 24th. The stock was sold at an average price of $318.80, for a total transaction of $797,000.00. Following the sale, the director now owns 8,480 shares of the company's stock, valued at approximately $2,703,424. This represents a 22.77% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Paul A. Mahon sold 11,000 shares of the firm's stock in a transaction dated Thursday, May 29th. The shares were sold at an average price of $316.07, for a total value of $3,476,770.00. Following the completion of the sale, the executive vice president now directly owns 36,781 shares in the company, valued at approximately $11,625,370.67. The trade was a 23.02% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 56,500 shares of company stock valued at $16,923,950 in the last 90 days. Insiders own 10.30% of the company's stock.

United Therapeutics Price Performance

Shares of NASDAQ UTHR opened at $325.82 on Friday. United Therapeutics Co. has a one year low of $266.98 and a one year high of $417.82. The business's fifty day moving average price is $301.06 and its 200-day moving average price is $333.58. The stock has a market capitalization of $14.70 billion, a PE ratio of 14.31, a P/E/G ratio of 0.97 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 EPS for the quarter, beating analysts' consensus estimates of $6.29 by $0.34. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm had revenue of $794.40 million for the quarter, compared to analysts' expectations of $726.82 million. During the same quarter in the prior year, the firm earned $6.17 EPS. The business's revenue for the quarter was up 17.2% compared to the same quarter last year. As a group, equities analysts expect that United Therapeutics Co. will post 24.48 EPS for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.